Argent Biopharma (AU:RGT) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Argent BioPharma is set to delist from the London Stock Exchange by the end of December 2024, focusing its listing efforts on the Australian Securities Exchange and the OTCQB Venture Market. This strategic move aims to streamline operations and boost administrative efficiency while keeping the door open for potential U.S. market opportunities. Investors should prepare for the last trading day on the LSE and consult advisors for future trading options.
For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.